Phase 2 Mesothelioma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with mesothelioma (a type of cancer affecting the lining of organs) that has spread or cannot be removed by surgery, and you have not yet received any systemic (whole-body) treatment — this applies to both chest (pleural) and non-chest forms (Cohort A)
- You have been diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) with specific gene changes (exon 19 deletion or exon 21 L858R mutation), with or without previous treatment with the drug Osimertinib (Cohort B)
- You have been diagnosed with mesothelioma specifically affecting the lining of the lungs (pleural) that has spread or cannot be removed, and you have not yet received chemotherapy (Cohort C)
- Your cancer can be measured using standard imaging methods
- You are generally well enough to carry out light activity and care for yourself (a standard fitness score of 0 or 1 on a scale used by doctors)
- Your liver, kidneys, and blood cell production are working well enough (confirm with trial site)
Who may not be able to join:
- You have cancer that has spread to the brain or a tumour starting in the brain or central nervous system
- You have a history of cancer spreading to the membranes surrounding the brain or spinal cord
- You currently have a serious bacterial, viral, or fungal infection that requires ongoing treatment
- You are known to be HIV positive, or have active Hepatitis B or Hepatitis C
- You have significant heart or cardiovascular disease, or have previously received treatments known to damage the heart
- You have an abnormal heart electrical reading of a specific type (QTcF interval over 470 msec) (confirm with trial site)
- You have another active cancer that could interfere with how the study results are measured
- You are currently pregnant or breastfeeding
- You have previously been treated with a type of drug called a TEAD inhibitor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Neelesh Sharma, MD, Vivace Therapeutics
Phone: 650-627-7437
Australian sites
650-627-7437
650-627-7437
650-627-7437
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Occurrence of Dose Limiting Toxicity; Occurrence of General Toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.